Antisense oligonucleotide inhibition of hepatitis C virus (HCV) gene expression in livers of mice infected with an HCV-vaccinia virus recombinant

Antimicrobial Agents and Chemotherapy

Volumn 43, Issue 2, 1999, Pages 347-353

  Zhang, Hong ^d   Hanecak, Ronnie ^a,d   Brown Driver, Vickie ^d   Azad, Raana ^d   Conklin, Boyd ^d   Fox, Maureen C ^b,d   Anderson, Kevin P ^c,d  

^a Trega Biosciences Inc   (United States)

^b INVITROGEN CORPORATION   (United States)

^c ISIS Pharmaceuticals Inc ^*  (United States)

^d ISIS PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; ISIS 1082; ISIS 14803; ISIS 6547; OLIGODEOXYNUCLEOTIDE PHOSPHOROTHIOATE; UNCLASSIFIED DRUG; VIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; HEPATITIS C; HEPATITIS C VIRUS; HEPATITIS NON A NON B; MOUSE; NONHUMAN; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; VACCINIA VIRUS; VIRUS GENE; VIRUS RECOMBINANT;

EID: 0032995650     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.43.2.347     Document Type: Article

References (52)

1. Agrawal, S., and J. Lisziewicz. 1994. Potential for HIV-1 treatment with antisense oligonucleotides. J. Biotechnol. Healthcare 1:167-182.
2. Alt, M., R. Renz, P. H. Hofschneider, G. Paumgartner, and W. H. Caselmann. 1995. Specific inhibition of hepatitis C viral gene expression by antisense phosphorothioate oligonucleotides. Hepatology 22:707-717.
3. Anderson, K. P., M. C. Fox, V. Brown-Driver, M. J. Martin, and R. F. Azad. 1996. Inhibition of human cytomegalovirus immediate-early gene expression by an antisense oligonucleotide complementary to immediate-early RNA. Antimicrob. Agents Chemother. 40:2004-2011.
4. Azad, R. F., V. B. Driver, K. Tanaka, R. M. Crooke, and K. P. Anderson. 1993. Antiviral activity of a phosphorothioate oligonucleotide complementary to RNA of the human cytomegalovirus major immediate-early region. Antimicrob. Agents Chemother. 37:1945-1954.
5. Baker, B. F., S. S. Lot, T. P. Condon, S. Cheng-Flournoy, E. A. Lesnik, H. M. Sasmor, and C. F. Bennett. 1997. 2′-O-(2-methoxy)ethyl-modified anti-intercellular adhesion molecule 1 (ICAM-1) oligonucleotides selectively increase the ICAM-1 mRNA level and inhibit formation of the ICAM1 translation initiation complex in human umbilical vein endothelial cells. J. Biol. Chem. 272:11994-12000.
6. Bartenschlager, R., L. Ahlborn-Laake, J. Mous, and H. Jacobsen. 1994. Kinetic and structural analyses of hepatitis C virus polyprotein processing. J. Virol. 68:5045-5055.
7. Bennett, C. F., D. Kornbrust, S. Henry, K. Stecker, R. Howard, S. Cooper, S. Dutson, W. Hall, and H. I. Jacoby. 1997. An ICAM-1 antisense oligonucleotide prevents and reverses dextran sulfate sodium-induced colitis in mice. J. Pharm. Exp. Ther. 280:988-1000.
8. Bisceglie, A. M. D., L. H. Simpson, M. T. Lotze, and J. H. Hoofnagle. 1994. Development of hepatocellular carcinoma among patients with chronic liver disease due to hepatitis C viral infection. J. Clin. Gastroenterol. 19:222-226.
9. Boggs, R. T., K. McGraw, T. Condon, S. Flournoy, P. Villiet, C. F. Bennett, and B. P. Monia. 1997. Characterization of modulation of immune stimulation by modified oligonucleotides. Antisense Nucleic Acid Drug Dev. 7:461-471.
10. Cabot, B., J. I. Esteban, M. Martell, J. Genesca, V. Vargas, R. Esteban, J. Guardia, and J. Gomez. 1997. Structure of replicating hepatitis C virus (HCV) quasispecies in the liver may not be reflected by analysis of circulating HCV viron. J. Virol. 71:1732-1734.
11. Chakrabarti, S., K., Brechung, and B. Moss. 1985. Vaccinia virus expression vector: coexpression of β-galactosidase provides visual screening of recombinant virus plaques. Mol. Cell. Biol. 5:3403-3409.
12. Chien, D. Y., Q.-L. Choo, R. Ralston, R. Spaete, M. Tong, M. Houghton, and G. Kuo. 1993. Persistence of HCV despite antibodies to both putative envelope glycoproteins. Lancet 342:933.
13. Choo, Q.-L., K. H. Richman, J. H. Han, K. Berger, C. Lee, C. Dong, C. Gallegos, D. Coit, A. Medina-Selby, P. J. Barr, A. J. Weiner, D. W. Bradley, G. Kuo, and M. Houghton. 1991. Genetic organization and diversity of the hepatitis C virus. Proc. Natl. Acad. Sci. USA 88:2451-2455.
14. Condon, T. P., and C. F. Bennett 1996. Altered mRNA splicing and inhibition of human E-selectin expression by an antisense oligonucleotide in human umbilical vein endothelial cells. J. Biol. Chem. 271:30398-30403.
15. Crooke, S. T. 1992. Therapeutic applications of oligonucleotides. Annu. Rev. Pharmcol. Toxicol. 32:329-376.
16. Crooke, S. T. 1995. Oligonucleotide therapeutics, p. 863-900. In M. E. Wolff (ed.), Burger's medicinal chemistry and drug discovery, 5th ed., vol. 1. John Wiley & Sons, Inc., New York, N.Y.
17. Davis, G. L., J. N. Lau, and H. L. Lim. 1994. Therapy for chronic hepatitis C. Viral Hepatitis 23:603-613.
18. Dean, N., R. McKay, L. Miraglia, R. Howard, S. Cooper, J. Giddings, P. Nicklin, L. Meister, R. Ziel, T. Geiger, M. Muller, and D. Fabbro. 1996. Inhibition of growth of human tumor cell line in nude mice by an antisense oligonucleotide inhibitor of protein kinase C-α expression. Cancer Res. 56:3499-3507.
19. Dean, N. M., and R. H. Griffey. 1997. Identification and characterization of second-generation antisense oligonucleotides. Antisense Nucleic Acid Drug dev. 7:229-233.
20. Earl, P. L., and B. Moss. 1991. Generation of recombinant vaccinia viruses. Curr. Protocols Mol. Biol. 2:16.17.1-16.17.16.
21. Galun, E., T. Burakova, M. Ketzinel, I. Lubin, E. Shezen, Y. Kahana, A. Eid, Y. Ilan, A. Rivkind, G. Pizov, D. Shouval, and Y. Reisner. 1995. Hepatitis C virus viremia in SCID->BNX mouse chimera. J. Infect. Dis. 172:25-30.
22. Grakoui, A., C. Wychowski, C. Lin, S. M. Feinstone, and C. M. Rice. 1993. Expression and identification of hepatitis C virus polyprotein cleavage products. J. Virol. 67:1385-1395.
23. Han, J., V. Shyamala, K. Richman, B. Brauer, B. Irvine, M. Urdea, P. Tekamp-Olson, G. Kuo, Q.-L. Choo, and M. Houghton. 1991. Characterization of terminal regions of hepatitis C viral RNA: identification of conserved sequences in the 5′ untranslated region and poly(A) tails at the 3′ end. Proc. Natl. Acad. Sci. USA 88:1711-1715.
24. Hanecak, R., V. Brown-Driver, M. C. Fox, R. F. Azad, S. Furusako, C. Nozaki, C. Ford, H. Sasmor, and K. P. Anderson. 1996. Antisense oligonucleotide inhibition of hepatitis C virus gene expression in transformed hepatocytes. J. Virol. 70:5203-5212.
25. Henry, S. P., D. Monteith, F. Bennett, and A. A. Levin. 1997. Toxicological and pharmacokinetic properties of chemically modified antisense oligonucleotide inhibitors of PKC-α and C-raf kinase. Anti-Cancer Drug Design 12:409-420.
26. Higgins, K. A., J. R. Perez, T. A. Coleman, K. Dorshkind, W. McComas, U. M. Sarmiento, C. A. Rosen, and R. Narayanan. 1993. Antisense inhibition of the p65 subunit of NF-κB blocks tumorigenicity and causes tumor regression. Proc. Natl. Acad. Sci. USA 90:9901-9905.
27. Ito, T., J. Mukaigawa, J. Zhou, Y. Hirabayashi, K. Mitamura, and K. Yasui. 1996. Cultivation of hepatitis C virus in primary hepatocyte culture from patients with chronic hepatitis C results in release of high litre infectious virus. J. Gen. Virol. 77:1043-1054.
28. Kolykhalov, A. A., S. M. Feinstone, and C. M. Rice. 1996. Identification of a highly conserved sequence element at the 37prime; terminus of hepatitis C virus genome RNA. J. Virol. 70:3363-3371.
29. Lin, C., B. D. Lindenbacb, B. M. Prahai, D. W. McCourt, and C. M. Rice. 1994. Processing in the hepatitis C virus E2-NS2 region: identification of p7 and two distinct E2-specific products with different C termini. J. Virol. 68:5063-5073.
30. Lu, H. H., and E. Wimmer. 1996. Poliovirus chimeras replicating under the translational control of genetic elements of hepatitis C virus reveal unusual properties of the internal ribosomal entry site of hepatitis C virus. Proc. Natl. Acad. Sci. USA 93:1412-1417.
31. Martell, M., J. I. Esteban, J. Quer, V. Vargas, R. Esteban, C. Guardia, and J. Gomez. 1994. Dynamic behavior of hepatitis C quasispecies in patients undergoing orthotopic liver transplantation. J. Virol. 68:3425-3436.
32. Monia, B. P., J. F. Johnston, T. Geiger, M. Muller, and D. Fabbro. 1996. Antitumor activity of a phosphorothioate antisense oligonucleotide targeted against C-raf kinase. Nat. Med. 2:668-675.
33. Monia, B. P., H. Sasmor, J. F. Johnston, S. M. Freier, E. A. Lesnik, M. Muller, T. Geiger, K.-H. Altmann, H. Moser, and D. Fabbro. 1996. Sequence-specific antitumor activity of a phosphorothioate oligonucleotide targeted to human C-raf kinase supports an antisense mechanism of action in vivo. Proc. Natl. Acad. Sci. USA 93:15481-15484.
34. Monteith, D. K., S. P. Henry, R. B. Howard, S. Flournoy, A. A. Levin, C. F. Bennett, and S. T. Crooke. 1997. Immune stimulation - a class effect of phosphorothioate oligodeoxynucleotides in rodents. Anti-Cancer Drug Design 12:421-432.
35. Nomura, H., Y. Kimmura, H. Tada, C. Hisano, C. Morita, O. Okamoto, G. Shiraishi, and S. Kashiwagi. 1996. Predictive factors of a response to interferon therapy in chronic hepatitis C. J. Clin. Gastroenterol. 23:185-190.
36. Offensperger, W.-B., S. Offensperger, E. Walter, K. Teubner, G. Igloi, H. E. Blum, and W. Gerok. 1993. In vivo inhibition of duck hepatitis B virus replication and gene expression by phosphorothioate modified antisense oligonucleotides. EMBO J. 12:1257-1262.
37. Raviprakash, K., K. Liu, M. Matteucci, R. Wagner, R. Riffenburgh, and M. Carl. 1995. Inhibition of dengue virus by novel, modified antisense oligonucleotides. J. Virol. 69:61-74.
38. Resnick, R. H., and R. Koff. 1993. Hepatitis C-related hepatocellular carcinoma: prevalence and significance. Arch. Intern. Med. 153:1672-1677.
39. Rijnbrand, R., P. Bredenbeek, T. Straaten, L. Whetter, G. Inchauspe, S. Lemon, and W. Spaan. 1995. Almost the entire 5′ nontranslated region of hepatitis C virus is required for cap-independent translation. FEBS Lett. 365:115-119.
40. Santolini, E., G. Migliaccio, and N. L. Monica. 1994. Biosynthesis and biochemical properties of the hepatitis C virus core protein. J. Virol. 68: 3631-3541.
41. Sharara, A. I., C. M. Hunt, and J. D. Hamilton. 1996. Hepatitis C. Ann. Intern. Med. 125:658-668.
42. Shimizu, Y. K., A. Iwamoto, M. Hijikata, and R. H. Purcell. 1992. Evidence for in vitro replication of hepatitis C virus genome in a human T-cell line. Proc. Natl. Acad. Sci. USA 89:5477-5481.
43. Takamizawa, A., C. Mori, I. Fuke, S. Manabe, S. Murakami, J. Fujita, E. Onishi, T. Andoh, I. Yoshida, and H. Okayama. 1991. Structure and organization of the hepatitis C virus genome isolated from human carriers. J. Virol. 65:1105-1113.
44. Tanaka, T., N. Kato, M.-J. Cho, K. Sugiyama, and K. Shimotohno. 1996. Structure of the 3′ terminus of the hepatitis C virus genome. J. Virol. 70:3307-3312.
45. Tsukiyama-Kohara, K., N. Iizuka, M. Kohara, and A. Nomoto. 1992. Internal ribosome entry site within hepatitis c virus RNA. J. Virol. 66:1476-1483.
46. Vidalin, O., M. E. Major, B. Rayner, J.-L. Imbach, C. Trepo, and G. Inchauspe. 1996. In vitro inhibition of hepatitis C virus gene expression by chemically modified antisense oligodeoxynucleotides. Antimicrob. Agents Chemother. 40:2337-4804.
47. Wang, C., S.-Y. Le, and A. Siddiqui. 1995. An RNA pseudoknot is an essential structural element of the internal ribosome entry site located within the hepatitis C virus 5′ noncoding region. RNA 1:526-537.
48. Weiner, A., A. Erickson, J. Kansopon, K. Crawford, E. Muchmore, A. L. Hughes, M. Houghton, and C. M. Walker. 1995. Persistent hepatitis C virus infection in a chimpanzee is associated with emergence of a cytotoxic T lymphocyte escape variant. Proc. Natl. Acad. Sci. USA 92:2755-2759.
49. Yamada, N., K. Tanihara, A. Takada, T. Yorihuzi, M. Isutsumi, H. Shimomura, T. Tsuji, and T. Date. 1996. Genetic organization and diversity of the 3′ noncoding region of the hepatitis C virus genome. Virology 223:255-261.
50. Yoo, B., M. Selby, J. Choe, B. Suh, S. Choi, J. Joh, G. Nuovo, H.-S. Lee, M. Houghton, and J. Han. 1995. Transfection of a differentiated human hepatoma cell line (Huh7) with in vitro-transcribed hepatitis C virus (HCV) RNA and establishment of a long-term culture persistently infected with HCV. J. Virol. 69:32-38.
51. Zein, N. N., J. Rakela, E. L. Krawitt, K. R. Reddy, T. Tominaga, D. H. Persing, and C. S. Group. 1996. Hepatitis C virus genotypes in the united states: epidemiology, pathogenicity, and response to interferon therapy. Ann. Intern. Med. 125:634-639.
52. Zhao, Q., J. Timsamani, R. Zhou, and S. Agrawal. 1997. Pattern and kinetics of cytokine production following administration of phosphorothioate oligonucleotides in mice. Antisense Nucleic Acid Drug Dev. 7:495-502.